SCHEMBL5639092

SCHEMBL5639092

N[C@@H]1CCCCN(C(=O)C2CC2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.42
TSHR P16473 4/20 0.41
CYP3A4 P08684 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 1/20 0.41
APEX1 P27695 1/20 0.41
DPP4 P27487 4/20 0.40
BRD4 O60885 1/20 0.40
ATAD2 Q6PL18 1/20 0.40
POLB P06746 2/20 0.39
ALDH1A1 P00352 4/20 0.38
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.36
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636144 0.95 TSHR (0.46) HPGDTSHRCYP3A4TDP1MAPT
SCHEMBL1114602 0.81 CYP3A4 (0.44) HPGDTSHRCYP3A4TDP1MAPT
SCHEMBL5638082 0.80 CYP3A4 (0.42) TSHRCYP3A4TDP1MAPTAPEX1
SCHEMBL5639256 0.79 CYP3A4 (0.41) HPGDTSHRCYP3A4TDP1MAPT
SCHEMBL5638540 0.76 CYP3A4 (0.39) TSHRCYP3A4TDP1MAPTAPEX1
Hydrochloric Acid SCHEMBL10797178 0.76 ALDH1A1 (0.41) TSHRCYP3A4TDP1MAPTAPEX1
SCHEMBL5637432 0.75 HTT (0.50) TSHRCYP3A4DPP4POLBALDH1A1
SCHEMBL5638521 0.73 HTT (0.53) TSHRPOLBALDH1A1HTTKMT2A
SCHEMBL5636865 0.73 HTT (0.49) TSHRDPP4POLBALDH1A1HTT
SCHEMBL5639089 0.73 DPP4 (0.40) TSHRCYP3A4TDP1MAPTAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 HPGD 2281/4885TSHR 667/4885CYP3A4 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.